Screener
Climb Bio, Inc. CLYM Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,373 | $17,327 |
| General and administrative | 5,838 | 5,691 |
| Total operating expenses | 15,211 | 23,018 |
| Loss from operations | (15,211) | (23,018) |
| Other income (expense): | ||
| Interest income | 1,514 | 2,287 |
| Foreign currency (loss) | (25) | (50) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s total operating expenses?
- Climb Bio, Inc. (CLYM) reported total operating expenses of $15.21M in Q1 2026.
- How has Climb Bio, Inc.'s total operating expenses changed year-over-year?
- Climb Bio, Inc.'s total operating expenses decreased by 33.9% year-over-year, from $23.02M to $15.21M.
- What is the long-term trend for Climb Bio, Inc.'s total operating expenses?
- Over 4 years (2021 to 2025), Climb Bio, Inc.'s total operating expenses has grown at a 17.5% compound annual growth rate (CAGR), from $35.67M to $67.88M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Climb Bio, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude